AMBER GARNER: Open Payments
NPI 1750821740 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,462 in 77 payments from 18 companies in 2025. Trend: 2023 $1,318 · 2024 $1,560 · 2025 $1,462
Food & beverage: $1,462
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $468 |
| AstraZeneca Pharmaceuticals LP | 8 | $146 |
| Novartis Pharmaceuticals Corporation | 7 | $142 |
| Daiichi Sankyo Inc. | 5 | $120 |
| Janssen Biotech, Inc. | 3 | $88 |
| PFIZER INC. | 4 | $76 |
| Eisai Inc. | 4 | $74 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Merck Sharp & Dohme LLC | 3 | $49 |
Products named: EPKINLY, ENHERTU, KISQALI, IMFINZI, Lenvima, VENCLEXTA, IMBRUVICA, IBRANCE.
Industry payments across AR — which companies pay providers there.
